Meeting
2022 ASCO Annual Meeting
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Presenter
Bruno Sangro, MD, PhD
Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03298451
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4074)
DOI
10.1200/JCO.2022.40.16_suppl.4074
Abstract #
4074
Poster Bd #
62
Abstract Disclosures
Similar Videos & Slides
Speaker: Manish A. Shah, MD
Videos & Slides
2023 ASCO Annual Meeting
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
Speaker: George Lau, MD, FRCP
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Speaker: Ghassan K. Abou-Alfa, MBA, MD
Videos & Slides
2020 Gastrointestinal Cancers Symposium
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
Speaker: Peter R. Galle, MD, PhD